Operator: Thank you. Our next question comes from the line of Frank Takkinen from Lake Street Capital Markets. Please go ahead.
Frank Takkinen: I’ll also echo my congratulations. Maybe to start with one more on the comment you made about continued momentum through the first quarter of the year. I think last year in the first quarter of 2022, you had something like three transactions. You had nine transactions in the fourth quarter of in 2022. Can you maybe speak directionally versus those metrics, how you’re feeling the placements could shake out in the first quarter of this year?
Ryan Rhodes: Yes. So Frank, usually, Q4 obviously is a strong quarter for most companies, inclusive of us. So we finished the year strong. There is the seasonality coming off the end of the year and then kind of ramping your growth throughout the following year. So, I think we’re off to a very good start for 2023. We’re still a few days away from closing the quarter. But I think, directionally, we’re heading in the right direction. We have a good playbook and plan we’re executing on. The team is working hard. So again, we would continue to kind of follow the patterns of growth that we would have probably seen early on last year. And again, we still got a couple more days here before the quarter ends, and we’re working hard to close every sale.
Frank Takkinen: Got it. Okay. That’s good color. And then secondly, wanted to ask on your comment of positive momentum in the advancement of U.S. society guidelines with focal ablation in the press release, I think you spoke about this in some — to some extent throughout the call today, but I was hoping you could speak about that a little bit more in depth and maybe talk about the impact of the recent data announced a couple of weeks ago and how that could influence those guideline decisions and conversations?
Ryan Rhodes: Yes. So again, we see more data coming out, and I’ll talk about that being the HIFU study, which was published study that has been under the authorization of Professor is showing very good oncologic control results comparatively to surgery. So again, we’re seeing more of this data coming out, these studies as well as the randomized clinical trial that is still underway in Norway, again, showing the efficacy and showing the results around oncologic control. We’re excited because we think those studies are performed with high discipline, and we’d expect those results to continue to be reproducible out in the markets. So, in terms of guideline development, we have a notable installed base of leading cancer centers.
And so, one of our missions is to work closely with them and see where they can possibly through the data that they’re tracking, we will use some of that data to help shape and build new guideline changes. And again, things like reimbursement on the commercial side, as brought up earlier, will be influenced as the volume and the procedures increase. And again, we continue to drive increases in our procedure volume. So that’s another data point as we look to impact either guideline change and/or reimbursement change at a commercial level.
Frank Takkinen: Okay. And then last one, I was hoping you could comment on any utilization trends you’re experiencing year-to-date since the implementation of the new reimbursement regime? And then if you could also touch on expected ASP changes specifically within the consumable piece of the sale.
Ryan Rhodes: Yes. So since going back to the — can you repeat that question again?
Frank Takkinen: Just the utilization trends of what the systems are. Yes and if they’re — if under the new reimbursement that’s gone into effect at the beginning of this year, if you’ve had the ability to raise price at all on disposable.
